Using our SHM-XEL™ platform, AnaptysBio is building an internal pipeline of novel therapeutic antibody product candidates for the treatment of autoimmune and other serious medical diseases. We seek to establish design goals and development strategies to provide the potential for our product candidates to represent best-in-class opportunities. AnaptysBio’s overall product portfolio includes both our internal and partnered product programs.
|